Structural Characterization of Gene Transfer Vectors - PowerPoint PPT Presentation

1 / 13
About This Presentation
Title:

Structural Characterization of Gene Transfer Vectors

Description:

Interrupts E3B 10.5K, 14.6K, 14.7K genes. Salmon, human, Drosophila homologies ... Generation of replication competent viruses: retrovirus, adenovirus. Other mutations ... – PowerPoint PPT presentation

Number of Views:25
Avg rating:3.0/5.0
Slides: 14
Provided by: steve105
Learn more at: http://www.fda.gov
Category:

less

Transcript and Presenter's Notes

Title: Structural Characterization of Gene Transfer Vectors


1
Structural Characterization of Gene Transfer
Vectors
  • BRMAC
  • November 16, 2000

2
(No Transcript)
3
Structural Characterization
  • Purpose
  • vector produced has expected characteristics
  • vector production is reliable
  • Methods
  • Restriction map
  • PCR
  • Nucleotide sequence

4
Impact Safety, Efficacy Production
  • Safety
  • replication competent virus
  • altered vector backbone
  • altered transgene
  • Efficacy
  • Production process

5
Sources of Genetic Alterations
  • Incompletely characterized vector backbones
  • intermediates not always well characterized
  • Instability during vector manufacture
  • recombination/rearrangements
  • mutation

6
Incompletely Characterized Intermediates
Promoter Transgene
ITR
ITR
AD 5 deleted E3
646 bp insert Interrupts E3B 10.5K, 14.6K, 14.7K
genes Salmon, human, Drosophila homologies
132-aa ORF, no protein homologies RNA detected
by RT-PCR Protein expression ?
7
Genetic Instability During Manufacture
  • Examples
  • Generation of replication competent viruses
    retrovirus, adenovirus
  • Other mutations

8
Genetic Changes in Vector Manufacture
Input Virus
9
Recommendations
  • Current
  • Early phase of development
  • sequence appropriate portions of vectors
  • or restriction maps plus protein characterization
  • Proposed
  • Before phase I
  • complete sequence of intermediates and vectors
  • lt 40 KB
  • sequence intermediates introduced and flanking
    regions for vectors gt 40 KB
  • complete sequence before phase II

10
Timing and Extent of Characterization
  • Before phase I
  • sequence intermediates and all or portion of
    vector before initiation of clinical trial
  • Product lot
  • sequence
  • other methods

11
Sequence Data Analysis
  • Comparison to expected sequence
  • Analysis for open reading frames
  • Comparisons to nucleotide and protein data bases

12
Unexpected Sequences
  • What additional experiments should be done to
    examine effects of unexpected sequences?
  • Vector characterization
  • Preclinical studies
  • Patient follow-up

13
Summary
  • Current recommendations for vector sequencing
  • Current information reveals unexpected genetic
    material
  • Considering more rigorous structural
    characterization
Write a Comment
User Comments (0)
About PowerShow.com